Skip to main content
. Author manuscript; available in PMC: 2014 Mar 13.
Published in final edited form as: J Endocrinol. 2010 Nov 10;208(2):171–182. doi: 10.1677/JOE-10-0338

Figure 2.

Figure 2

RT-PCR and western blotting for expression of estrogen receptor beta (ERβ) and estrogen receptor alpha (ERα). Treatment groups: control (CON); 50 nM PPT (24 h); 50 nM DPN (24 h); 150 nM EST (24 h); 10 μM ICI (24 h); 50 ng/ml TNF-α (24 h); 50 ng/ml TNF-α (24 h)+PPT (treatment at 15 min post TNF-α exposure); 50 ng/ml TNF-α (24 h)+PPT (treatment at 15 min post TNF-α exposure)+ICI (treatment at 20 min post TNF-α exposure); 50 ng/ml TNF-α (24 h)+DPN (treatment at 15 min post TNF-α exposure); 50 ng/ml TNF-α (24 h)+DPN (treatment at 15 min post TNF-α exposure)+ICI (treatment at 20 min post TNF-α exposure); 50 ng/ml TNF-α (24 h)+EST (treatment at 15 min post TNF-α exposure); 50 ng/ml TNF-α (24 h)+EST (treatment at 15 min post TNF-α exposure)+ICI (treatment at 20 min post TNF-α exposure). Representative pictures to show levels of ERβ, ERα, and GAPDH at mRNA (RT-PCR) (A) and protein levels (western blotting) (B). (C) Bar graphs indicating the changes in expression of ERβ and ERα over CON. *P<0·05 compared to control.